Epo Omega Opportunity
Purchased assets and global rights to recombinant erythropoietin for treatment of anemia
Strategic entry into $7 billion, rapidly growing market
Currently selling Epomax in smaller markets where approved
Plan regulatory filings for additional countries by year-end
Targeted launches for Europe in 2006 and Japan 2007